Mylan and Biocon, announced on 28 April 2020 the launch of their pegfilgrastim biosimilar, Fulphila, in Canada. This is the second biosimilar from the pair to be launched in the country.
The FDA has approved on 17 My 2012 generic versions of Plavix (clopidogrel) for Dr Reddy's Laboratories, Gate Pharmaceuticals, Mylan...
Teva Pharmaceutical Industries Ltd. announced a proposal to acquire all of the outstanding shares of Mylan N.V. in a transaction...
Atazanavir Mylan, co-administered with low dose ritonavir, is indicated for the treatment of HIV-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products (see section 4.2). Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 PI mutations). The choice of Atazanavir Mylan in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient's treatment history (see sections 4.4 and 5.1).
Teva Pharmaceutical Industries announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary...
Mylan N.V. announced that it has officially commenced its formal offer to acquire all outstanding ordinary shares of Perrigo Company...
A US District Court in a case brought by Hospira has invalidated four patents extending to 2020 for Cubicin (daptomycin)from...
Mylan N.V. announced that Mylan has made a proposal to acquire Perrigo Company plc in a cash-and-stock transaction that would...
Mylan N.V. announced that the FDA has approved Mylan's Abbreviated New Drug Applications (ANDAs) for Glatiramer Acetate Injection 40 mg/mL...
The FDA has approved the first generic versions of Singulair (montelukast sodium)from AstraZeneca for use in adults and children to...